Log In
BCIQ
Print this Print this
 

serlopitant (VPD-737) (formerly MK-0594)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionTachykinin receptor (TACR1; NK1R) antagonist
Molecular Target Tachykinin receptor (TACR1) (NK1R)
Mechanism of ActionTachykinin receptor (TACR1) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationItch
Indication DetailsTreat chronic pruritus; Treat prurigo nodularis; Treat pruritus associated with atopic dermatitis; Treat pruritus following burn injury
Regulatory Designation
PartnerJapan Tobacco Inc.;
Menlo Therapeutics Inc.;
Torii Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/10/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today